{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T05:32:15Z","timestamp":1782538335810,"version":"3.54.5"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007764","name":"Lanzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2024-4-2"],"award-info":[{"award-number":["2024-4-2"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007764","name":"Lanzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2024-8-27"],"award-info":[{"award-number":["2024-8-27"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007764","name":"Lanzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2024-8-30"],"award-info":[{"award-number":["2024-8-30"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012899","name":"Lanzhou University","doi-asserted-by":"publisher","award":["20240260001"],"award-info":[{"award-number":["20240260001"]}],"id":[{"id":"10.13039\/100012899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012899","name":"Lanzhou University","doi-asserted-by":"publisher","award":["20240260017"],"award-info":[{"award-number":["20240260017"]}],"id":[{"id":"10.13039\/100012899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bmc.2025.118282","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T12:24:49Z","timestamp":1750076689000},"page":"118282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["10PL8 and 2fPL8 inhibit gastric cancer cell proliferation by targeting degradation of CDK6 proteins to arrest the cell cycle"],"prefix":"10.1016","volume":"128","author":[{"given":"Hao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongkun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shude","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixue","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqian","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-4568","authenticated-orcid":false,"given":"Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118282_b0005","doi-asserted-by":"crossref","first-page":"724","DOI":"10.2174\/0113894501313781240627062206","article-title":"Potential Target of CDK6 Signaling Pathway for Cancer Treatment","volume":"25","author":"Basnet","year":"2024","journal-title":"Current Drug targets"},{"key":"10.1016\/j.bmc.2025.118282_b0010","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bmc.2025.118282_b0015","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4\/6 Inhibitors via the Hippo Pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer cell"},{"key":"10.1016\/j.bmc.2025.118282_b0020","doi-asserted-by":"crossref","first-page":"776","DOI":"10.2174\/0929867329666220729152741","article-title":"Multi or Single-Kinase Inhibitors to Counteract Drug Resistance in Cancer: what is New?","volume":"30","author":"Pecoraro","year":"2023","journal-title":"Current Medicinal chemistry"},{"key":"10.1016\/j.bmc.2025.118282_b0025","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1128\/MCB.01823-08","article-title":"Differential regulation of cyclin-dependent kinase 4 (CDK4) and CDK6, evidence that CDK4 might not be activated by CDK7, and design of a CDK6 activating mutation","volume":"29","author":"Bockstaele","year":"2009","journal-title":"Molecular and cellular biology"},{"key":"10.1016\/j.bmc.2025.118282_b0030","first-page":"28","article-title":"Recent Progress in CDK4\/6 Inhibitors and PROTACs","author":"Wang","year":"2023","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.bmc.2025.118282_b0035","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1021\/acs.jmedchem.2c00710","article-title":"Synthetic Approaches to the New Drugs Approved during 2020","volume":"65","author":"Flick","year":"2022","journal-title":"Journal of Medicinal chemistry"},{"key":"10.1016\/j.bmc.2025.118282_b0040","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S1470-2045(11)70102-4","article-title":"Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"12","author":"Adams","year":"2011","journal-title":"The Lancet. Oncology"},{"key":"10.1016\/j.bmc.2025.118282_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/md21070412","article-title":"1,3,4-Oxadiazole and 1,3,4-Thiadiazole Nortopsentin Derivatives against Pancreatic Ductal Adenocarcinoma: Synthesis, Cytotoxic activity, and Inhibition of CDK1","volume":"21","author":"Carbone","year":"2023","journal-title":"Marine drugs"},{"key":"10.1016\/j.bmc.2025.118282_b0050","article-title":"Insights on Cancer Cell Inhibition, Subcellular Activities, and Kinase Profile of Phenylacetamides Pending 1H-Imidazol-5-one Variants","volume":"12","author":"Khayat","year":"2021","journal-title":"Frontiers in pharmacology"},{"key":"10.1016\/j.bmc.2025.118282_b0055","first-page":"263","article-title":"Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications. Biochimica et biophysica acta","volume":"1869","author":"Camorani","year":"2018","journal-title":"Reviews on cancer"},{"key":"10.1016\/j.bmc.2025.118282_b0060","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacological research"},{"key":"10.1016\/j.bmc.2025.118282_b0065","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2006.07.4658","article-title":"What is the right dose? the elusive optimal biologic dose in phase I clinical trials","volume":"24","author":"Adjei","year":"2006","journal-title":"Journal of Clinical Oncology\u202f: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.bmc.2025.118282_b0070","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nbt.2152","article-title":"The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome","volume":"30","author":"Paik","year":"2012","journal-title":"Nature biotechnology"},{"key":"10.1016\/j.bmc.2025.118282_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112993","article-title":"PROTACs to address the challenges facing small molecule inhibitors","volume":"210","author":"Mart\u00edn-Acosta","year":"2021","journal-title":"European journal of medicinal chemistry"},{"key":"10.1016\/j.bmc.2025.118282_b0080","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bbamcr.2013.06.031","article-title":"Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system","volume":"1843","author":"Amm","year":"2014","journal-title":"Biochimica et Biophysica acta"},{"key":"10.1016\/j.bmc.2025.118282_b0085","doi-asserted-by":"crossref","unstructured":"Chamberlain PP, Hamann LG. Development of targeted protein degradation therapeutics. Nature chemical biology.2019;15:937-944.","DOI":"10.1038\/s41589-019-0362-y"},{"key":"10.1016\/j.bmc.2025.118282_b0090","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/anie.201507634","article-title":"Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL","volume":"55","author":"Lai","year":"2016","journal-title":"Angewandte Chemie (International ed. in English)"},{"key":"10.1016\/j.bmc.2025.118282_b0095","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nature Chemical biology"},{"key":"10.1016\/j.bmc.2025.118282_b0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2025.118282_b0105","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bcp.2016.07.017","article-title":"New strategy for renal fibrosis: Targeting Smad3 proteins for ubiquitination and degradation","volume":"116","author":"Wang","year":"2016","journal-title":"Biochemical pharmacology"},{"key":"10.1016\/j.bmc.2025.118282_b0110","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41586-019-0917-9","article-title":"Ultra-large library docking for discovering new chemotypes","volume":"566","author":"Lyu","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118282_b0115","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41596-021-00659-2","article-title":"Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking","volume":"17","author":"Gentile","year":"2022","journal-title":"Nature protocols"},{"key":"10.1016\/j.bmc.2025.118282_b0120","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/d41586-021-03682-1","article-title":"A virtual drug-screening approach to conquer huge chemical libraries","volume":"601","author":"Deane","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118282_b0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/d41573-022-00002-8","article-title":"Screening ultra-large virtual libraries","volume":"21","author":"Crunkhorn","year":"2022","journal-title":"Nature Reviews. Drug discovery"},{"key":"10.1016\/j.bmc.2025.118282_b0130","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1021\/acs.jcim.0c00675","article-title":"ZINC20-a Free Ultralarge-Scale Chemical Database for Ligand Discovery","volume":"60","author":"Irwin","year":"2020","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.bmc.2025.118282_b0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: an open chemical toolbox","volume":"3","author":"O\u2019Boyle","year":"2011","journal-title":"J Cheminform"},{"key":"10.1016\/j.bmc.2025.118282_b0140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","article-title":"Small-molecule library screening by docking with PyRx","volume":"1263","author":"Dallakyan","year":"2015","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bmc.2025.118282_b0145","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","article-title":"Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance","volume":"15","author":"Chen","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bmc.2025.118282_b0150","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2025.118282_b0155","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2025.118282_b0160","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2013a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J Comput Chem"},{"key":"10.1016\/j.bmc.2025.118282_b0165","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1021\/jm901137j","article-title":"New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays","volume":"53","author":"Baell","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118282_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046902","article-title":"Exploring PHD fingers and H3K4me0 interactions with molecular dynamics simulations and binding free energy calculations: AIRE-PHD1, a comparative study","volume":"7","author":"Spiliotopoulos","year":"2012","journal-title":"PLoS one"},{"key":"10.1016\/j.bmc.2025.118282_b0175","doi-asserted-by":"crossref","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: a New Tool to Perform End-State Free Energy Calculations with GROMACS","volume":"17","author":"Vald\u00e9s-Tresanco","year":"2021","journal-title":"Journal of Chemical Theory and computation"},{"key":"10.1016\/j.bmc.2025.118282_b0180","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.1021\/acs.jmedchem.9b00353","article-title":"Discovery of Inhibitors of Aurora\/PLK Targets as Anticancer Agents","volume":"62","author":"Qi","year":"2019","journal-title":"Journal of Medicinal chemistry"},{"key":"10.1016\/j.bmc.2025.118282_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107221","article-title":"Novel spiroindoline derivatives targeting aldose reductase against diabetic complications: Bioactivity, cytotoxicity, and molecular modeling studies","volume":"145","author":"G\u00fcle\u00e7","year":"2024","journal-title":"Bioorganic chemistry"},{"key":"10.1016\/j.bmc.2025.118282_b0190","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1039\/D4MD00617H","article-title":"Novel benzenesulfonamides containing a dual triazole moiety with selective carbonic anhydrase inhibition and anticancer activity","volume":"16","author":"Buza","year":"2024","journal-title":"RSC Medicinal chemistry"},{"key":"10.1016\/j.bmc.2025.118282_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2024.125558","article-title":"Bioactivity, cytotoxicity, and molecular modeling studies of novel sulfonamides as dual inhibitors of carbonic anhydrases and acetylcholinesterase","volume":"410","author":"G\u00fcle\u00e7","year":"2024","journal-title":"Journal of Molecular Liquids"},{"key":"10.1016\/j.bmc.2025.118282_b0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-7899-1_1","article-title":"Molecular Descriptors for Structure-activity applications: a Hands-on Approach","volume":"1800","author":"Grisoni","year":"2018","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bmc.2025.118282_b0205","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1021\/ci300293f","article-title":"Plane of best fit: a novel method to characterize the three-dimensionality of molecules","volume":"52","author":"Firth","year":"2012","journal-title":"Journal of Chemical Information and modeling"},{"key":"10.1016\/j.bmc.2025.118282_b0210","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ddtec.2021.05.001","article-title":"Escape from planarity in fragment-based drug discovery: a physicochemical and 3D property analysis of synthetic 3D fragment libraries","volume":"38","author":"Hamilton","year":"2020","journal-title":"Drug Discovery Today. Technologies"},{"key":"10.1016\/j.bmc.2025.118282_b0215","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jclinepi.2021.11.032","article-title":"Sankey diagrams can clarify \u201cevidence attrition\u201d: a systematic review and meta-analysis of the effectiveness of rapid diagnostic tests for antimicrobial resistance","volume":"144","author":"Glover","year":"2022","journal-title":"Journal of Clinical epidemiology"},{"key":"10.1016\/j.bmc.2025.118282_b0220","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1158\/2159-8290.CD-17-0912","article-title":"CDK6 Antagonizes p53-Induced responses during Tumorigenesis","volume":"8","author":"Bellutti","year":"2018","journal-title":"Cancer discovery"},{"key":"10.1016\/j.bmc.2025.118282_b0225","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2025.118282_b0230","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1089\/cbr.2019.2904","article-title":"LncRNA LINC00974 Upregulates CDK6 to Promote Cell Cycle Progression in Gastric Carcinoma","volume":"34","author":"Gao","year":"2019","journal-title":"Cancer Biotherapy & radiopharmaceuticals"},{"key":"10.1016\/j.bmc.2025.118282_b0235","doi-asserted-by":"crossref","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and Letrozole in Advanced Breast Cancer. The New England journal of medicine.2016;375:1925-1936.","DOI":"10.1056\/NEJMoa1607303"},{"key":"10.1016\/j.bmc.2025.118282_b0240","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib As initial Therapy for Advanced Breast Cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"Journal of Clinical Oncology\u202f: Official Journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.bmc.2025.118282_b0245","doi-asserted-by":"crossref","unstructured":"Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. The New England journal of medicine.2020;382:514-524.","DOI":"10.1056\/NEJMoa1911149"},{"key":"10.1016\/j.bmc.2025.118282_b0250","doi-asserted-by":"crossref","first-page":"7575","DOI":"10.1021\/acs.jmedchem.9b00871","article-title":"Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders","volume":"62","author":"Su","year":"2019","journal-title":"Journal of Medicinal chemistry"},{"key":"10.1016\/j.bmc.2025.118282_b0255","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-015-0194-5","article-title":"Palbociclib: a first-in-class CDK4\/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer","volume":"8","author":"Lu","year":"2015","journal-title":"Journal of Hematology & oncology"},{"key":"10.1016\/j.bmc.2025.118282_b0260","doi-asserted-by":"crossref","DOI":"10.3390\/md18110545","article-title":"Recent advances in Molecular Docking for the Research and Discovery of potential Marine Drugs","volume":"18","author":"Chen","year":"2020","journal-title":"Marine drugs"},{"key":"10.1016\/j.bmc.2025.118282_b0265","doi-asserted-by":"crossref","first-page":"8276","DOI":"10.1109\/TPAMI.2021.3103980","article-title":"Heatmap Regression via Randomized Rounding","volume":"44","author":"Yu","year":"2022","journal-title":"IEEE transactions on pattern analysis and machine intelligence"},{"key":"10.1016\/j.bmc.2025.118282_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2010.06.008","article-title":"Chemical probes of Escherichia coli uncovered through chemical-chemical interaction profiling with compounds of known biological activity","volume":"17","author":"Farha","year":"2010","journal-title":"Chemistry & biology"},{"key":"10.1016\/j.bmc.2025.118282_b0275","doi-asserted-by":"crossref","unstructured":"Nebenfuehr S, Kollmann K, Sexl V. The role of CDK6 in cancer. International journal of cancer.2020;147:2988-2995.","DOI":"10.1002\/ijc.33054"},{"key":"10.1016\/j.bmc.2025.118282_b0280","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez G. Introduction to \u201cIntramolecular Hydrogen Bonding 2018\u201d. Molecules (Basel, Switzerland).2019;24.","DOI":"10.3390\/molecules24162858"},{"key":"10.1016\/j.bmc.2025.118282_b0285","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: from Discovery to Therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discovery"},{"key":"10.1016\/j.bmc.2025.118282_b0290","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.bmc.2025.118282_b0295","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/bs.acr.2020.02.002","article-title":"Cyclin D-CDK4\/6 functions in cancer","volume":"148","author":"Gao","year":"2020","journal-title":"Advances in Cancer research"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625002238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:32:55Z","timestamp":1778574775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625002238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":59,"alternative-id":["S0968089625002238"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118282","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"10PL8 and 2fPL8 inhibit gastric cancer cell proliferation by targeting degradation of CDK6 proteins to arrest the cell cycle","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118282"}}